MX377531B - Terapia de combinación de un inhibidor del ensamble de la cápside del hbv y un interferón. - Google Patents

Terapia de combinación de un inhibidor del ensamble de la cápside del hbv y un interferón.

Info

Publication number
MX377531B
MX377531B MX2018005230A MX2018005230A MX377531B MX 377531 B MX377531 B MX 377531B MX 2018005230 A MX2018005230 A MX 2018005230A MX 2018005230 A MX2018005230 A MX 2018005230A MX 377531 B MX377531 B MX 377531B
Authority
MX
Mexico
Prior art keywords
interferon
combination therapy
capsid assembly
hbv capsid
assembly inhibitor
Prior art date
Application number
MX2018005230A
Other languages
English (en)
Other versions
MX2018005230A (es
Inventor
Fang Shen
Guang Yang
Hong Shen
Isabel Najera
Liping Shi
Lu Gao
Steffen Wildum
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2018005230A publication Critical patent/MX2018005230A/es
Publication of MX377531B publication Critical patent/MX377531B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a composiciones y métodos para tratar la infección por el virus de la hepatitis B. En particular, la presente invención está dirigida a una terapia de combinación que comprende la administración de un inhibidor del ensamble de cápside del HBV y un interferón para su uso en el tratamiento de infecciones por el virus de la hepatitis B.
MX2018005230A 2015-11-03 2016-10-31 Terapia de combinación de un inhibidor del ensamble de la cápside del hbv y un interferón. MX377531B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2015093688 2015-11-03
PCT/EP2016/076195 WO2017076791A1 (en) 2015-11-03 2016-10-31 Combination therapy of an hbv capsid assembly inhibitor and an interferon

Publications (2)

Publication Number Publication Date
MX2018005230A MX2018005230A (es) 2018-08-15
MX377531B true MX377531B (es) 2025-03-10

Family

ID=57223681

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018005230A MX377531B (es) 2015-11-03 2016-10-31 Terapia de combinación de un inhibidor del ensamble de la cápside del hbv y un interferón.

Country Status (12)

Country Link
US (2) US10596173B2 (es)
EP (1) EP3370759A1 (es)
JP (2) JP6668468B2 (es)
KR (1) KR102181168B1 (es)
CN (1) CN108135979A (es)
AU (1) AU2016349685A1 (es)
BR (1) BR112018009009A8 (es)
CA (1) CA2999944A1 (es)
HK (1) HK1255463A1 (es)
IL (1) IL258147A (es)
MX (1) MX377531B (es)
WO (1) WO2017076791A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3114128T3 (pl) * 2014-03-07 2019-06-28 F. Hoffmann-La Roche Ag Nowe skondensowane w pozycji 6 heteroarylodihydropirymidyny stosowane w leczeniu i profilaktyce zakażenia wirusem zapalenia wątroby typu B
CN107427514B (zh) * 2015-03-16 2021-07-13 豪夫迈·罗氏有限公司 使用tlr7激动剂和hbv衣壳装配抑制剂的组合治疗
MA43028B1 (fr) 2015-10-02 2021-09-30 Hoffmann La Roche Anticorps bispécifiques pour pd1 et tim3
BR102017010009A2 (pt) 2016-05-27 2017-12-12 Gilead Sciences, Inc. Compounds for the treatment of hepatitis b virus infection
UY37581A (es) 2017-02-02 2018-08-31 Gilead Sciences Inc Compuestos para el tratamiento de la infección por virus de la hepatitis b
KR102461885B1 (ko) 2017-04-03 2022-11-03 에프. 호프만-라 로슈 아게 항-pd-1 항체와 돌연변이 il-2 또는 il-15의 면역접합체
CA3052532A1 (en) 2017-04-05 2018-10-11 F. Hoffmann-La Roche Ag Bispecific antibodies specifically binding to pd1 and lag3
EP3645516A4 (en) 2017-06-27 2021-07-07 Janssen Pharmaceutica NV HETEROARYLDIHYDROPYRIMIDE DERIVATIVES AND METHODS OF TREATMENT OF HEPATITIS B INFECTIONS
KR20200032702A (ko) 2017-07-27 2020-03-26 지앙수 헨그루이 메디슨 컴퍼니 리미티드 피페라진 헤테로아릴 유도체, 그 제조 방법 및 의약에서 이의 용도
SG11202003320SA (en) * 2017-10-18 2020-05-28 Sunshine Lake Pharma Co Ltd Dihydropyrimidine compounds and uses thereof in medicine
EP3732177B1 (en) * 2017-12-28 2021-11-17 F. Hoffmann-La Roche AG Dihydropyrimidinylthiazole for the treatment and prophylaxis of hepatitis b virus infection
US11053235B2 (en) 2018-08-09 2021-07-06 Janssen Sciences Ireland Unlimited Company Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases
EP3873488B1 (en) 2018-10-31 2025-03-19 The University of Sydney Pharmaceutical compositions for use in treating an hbv or hdv infection
CA3124317A1 (en) * 2018-12-20 2020-06-25 Janssen Pharmaceutica Nv Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis b infections
AU2020249331B2 (en) 2019-03-25 2026-02-05 F. Hoffmann-La Roche Ag Solid forms of a compound of HBV core protein allosteric modifier
EP4031140A1 (en) * 2019-09-20 2022-07-27 F. Hoffmann-La Roche AG Method of treating hbv infection using a core protein allosteric modulator
WO2021063852A1 (en) * 2019-09-30 2021-04-08 F. Hoffmann-La Roche Ag Substituted pyrimidine for the treatment and prophylaxis of hepatitis b virus infection
CN116507611A (zh) * 2020-11-06 2023-07-28 佩勒梅德有限公司 新型衣壳组装抑制剂
CN115210237B (zh) * 2021-02-09 2023-11-14 上海维申医药有限公司 一种二氢嘧啶类化合物、其制备方法及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2514950B2 (ja) 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質,その製造法および中間体
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
HUT75533A (en) 1993-11-10 1997-05-28 Schering Corp Improved interferon polymer conjugates
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
WO2001045712A1 (de) * 1999-12-22 2001-06-28 Bayer Aktiengesellschaft Arzneimittelkombinationen gegen virale erkrankungen
WO2008154820A1 (fr) 2007-06-18 2008-12-24 Zhang, Zhongneng Thiazolyl-dihydropyrimidines à substitution carbéthoxy
WO2008154819A1 (fr) 2007-06-18 2008-12-24 Zhang, Zhongneng Thiazolyl-dihydropyrimidines à substitution carbéthoxy
PT2514750E (pt) 2007-06-18 2014-01-23 Sunshine Lake Pharma Co Ltd Tiazolil dihidropirimidinas substituídas com bromo-fenilo
CN101328170B (zh) 2007-06-18 2011-09-14 张中能 一种氟苯基-取代噻唑二氢嘧啶
MY182403A (en) * 2012-08-24 2021-01-25 Sunshine Lake Pharma Co Ltd Dihydropyrimidine compounds and their application in pharmaceuticals
CN103664925B (zh) 2012-09-07 2018-01-23 广东东阳光药业有限公司 杂芳基取代的二氢嘧啶类化合物及其在药物中的应用
CA2881322A1 (en) * 2012-09-10 2014-03-13 F. Hoffmann-La Roche Ag 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
PE20151951A1 (es) * 2013-05-17 2015-12-26 Hoffmann La Roche Heteroarildihidropirimidinas unidas por puentes en 6 para el tratamiento y la profilaxis de infeccion por el virus de la hepatitis b
CA2920415A1 (en) 2013-11-19 2015-05-28 Sunshine Lake Pharma Co., Ltd. Dihydropyrimidine compounds and their application in pharmaceuticals
JP6553059B2 (ja) * 2014-02-05 2019-07-31 ノヴィラ・セラピューティクス・インコーポレイテッド Hbv感染の治療のための併用療法
PL3114128T3 (pl) * 2014-03-07 2019-06-28 F. Hoffmann-La Roche Ag Nowe skondensowane w pozycji 6 heteroarylodihydropirymidyny stosowane w leczeniu i profilaktyce zakażenia wirusem zapalenia wątroby typu B

Also Published As

Publication number Publication date
US10596173B2 (en) 2020-03-24
KR20180058828A (ko) 2018-06-01
US20200276198A1 (en) 2020-09-03
JP2020100636A (ja) 2020-07-02
EP3370759A1 (en) 2018-09-12
JP2018531272A (ja) 2018-10-25
IL258147A (en) 2018-05-31
BR112018009009A2 (pt) 2018-10-30
US20180250301A1 (en) 2018-09-06
HK1255463A1 (zh) 2019-08-16
BR112018009009A8 (pt) 2019-02-26
CA2999944A1 (en) 2017-05-11
WO2017076791A1 (en) 2017-05-11
MX2018005230A (es) 2018-08-15
JP6668468B2 (ja) 2020-03-18
KR102181168B1 (ko) 2020-11-23
CN108135979A (zh) 2018-06-08
AU2016349685A1 (en) 2018-03-15

Similar Documents

Publication Publication Date Title
MX2018005230A (es) Terapia de combinacion de un inhibidor del ensamble de la capside del hbv y un interferon.
MX2022011756A (es) Tratamiento combinado con un agonista de tlr7 y un inhibidor del ensamblaje de la capsida del vhb.
JOP20180008A1 (ar) مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b
MX2021014771A (es) Tratamiento combinado con un agonista de tlr7 y un inhibidor de montaje de capsida de hbv.
MX2020011808A (es) Combinaciones y metodos que comprenden un inhibidor del ensamblaje de la capside.
JOP20170130A1 (ar) مركبات لمعالجة عدوى فيروس التهاب الكبد الوبائي b
UA117518C2 (uk) 6-конденсовані гетероарилдигідропіримідини для лікування та профілактики зараження вірусом гепатиту b
MX383447B (es) Combinación de un inhibidor de ensamblaje de cápsido y peginterferón alfa-2a y sus usos para tratar infecciones por virus de la hepatitis b (vhb).
EA201792069A1 (ru) Производные азокана и азонана и способы лечения инфекций гепатита в
PL3684377T3 (pl) Sposoby leczenia zakażenia wirusem zapalenia wątroby typu b
PH12018550150B1 (en) Elimination of hepatitis b virus with antiviral agents
EA201791515A1 (ru) Соединения пиразина для лечения инфекционных заболеваний
EA201790160A1 (ru) Способы лечения инфекций, вызываемых вирусами гепатита b и гепатита d
EP3370723A4 (en) TREATMENT OF HEPATITIS DELTA VIRUS INFECTION
MX2021010145A (es) Derivados de amida utiles en el tratamiento de una infeccion por vhb o de enfermedades inducidas por vhb.
PL3416675T3 (pl) Leczenie zakażenia wirusem zapalenia wątroby typu delta za pomocą interferonu lambda
EA201790771A1 (ru) Фармацевтические композиции длительного действия для лечения гепатита c
JOP20190214A1 (ar) ثنائي هيدرو إيندين-?-كربوكساميدات ونظائر منها بها استبدال، وطرق تستخدمها
EA201790776A1 (ru) Комбинированные композиции длительного действия и способы лечения гепатита с
IL271491A (en) Treatment of carcinoma of the liver characterized by hepatitis B virus infection
PH12018502320A1 (en) Reagents for treatment of hepatitis b virus (hbv) infection and use thereof
TR201910305T4 (tr) Viral enfeksiyonları tedavi etmek için bileşikler.
PL3710025T3 (pl) Biomasa sinic do zastosowania w leczeniu zakażenia wirusem zapalenia wątroby typu b
EA201892348A1 (ru) Комбинации и способы, включающие ингибитор сборки капсида
MX2021013594A (es) Derivados de amida utiles en el tratamiento de la infeccion por vhb o de enfermedades inducidas por vhb.

Legal Events

Date Code Title Description
FG Grant or registration